Fahima Dossa, MD PhD

Congratulations to @DrDrFoster of @Stanford University, recipient of the SSAT Career Development Award! 🎉 Dr. Foster’s work reflects the innovation and dedication that continue to advance the field of digestive diseases. #Surgery #AcademicMedicine #Research #StanfordUniversity

This is a great read on watch & wait in rectal cancer. B/c patients with local regrowth after WW have higher rates of distant mets, there has been an intuitive fear that regrowth is causal (i.e delaying TME permits metastatic seeding hence WW risky). The authors here argue (and I agree) that regrowth/metastases are manifestations of intrinsic aggressive tumor biology because: 1) no difference in time to surgery in patients w pCR/regrowth who developed mets vs. those who didn't (if delay were causal, would expect longer delay in patients who developed M1). 2) in OPRA secondary analysis, patients with cCR underwent least surgery/longest observation while those with incomplete response had surgery most frequently/immediately. But outcomes still tracked with response phenotype not timing of surgery (i.e. cCR did best). 3) tumor response itself is prognostic (i.e. even when all pts undergo TME, more regression after neoadjuvant therapy --> better DFS/DM). 4) modern tumor evolution data suggest metastatic spread mostly happens early. 5) chemo/radioresistance appears to be linked to metastatic potential (i.e. regrowth is a marker of aggressive biology not the mechanism itself). IMO a persuasive argument against hypothesis that regrowth seeds metastasis, but rather biology=dominant driver. @OncoAlert

@NiuSanford Thanks for this great summary of our work!

Thrilled to finally see this out - 🚨#Sarculator bayesian update for more refined risk estimates in extremity soft tissue sarcoma App📱update and @LancetOncology pub: sciencedirect.com/science/articl… Phenomenal work @DCalleMD, Gabriele Tine, et al. ! 👏🏽👏🏽

@jgong15 @JCO_ASCO Thanks so much!

@fdossa @JCO_ASCO Way to go @fdossa , an excellent read!

With ⤴️use of W&W for rectal cancer, how can we safely 🫸the limits? Is there a role for W&W in pts with *near* complete response or does this risk distant disease? More on the📊 and our recommendations for safe W&W practices: ascopubs.org/doi/10.1200/JC… @JCO_ASCO @DrGarciaAguilar

@DanielleHammo20 @HannahRAbrams Spider/radar diagram

@HannahRAbrams May I ask: what is this 📊 type called? Love it.

@HannahRAbrams Thanks for highlighting! This is probably clearer in the paper but we purposely framed all outcomes such that further from center = better (eg tolerability rather than toxicity) So niro had ⬆️toxicity (incl ovarian suppression) but most rapid effect💨(?differences in study pops)

New RCT data 📈 supporting the efficacy of Doxil for progressing desmoid tumors. Now 3 options supported by level 1 data - but how to choose? 🧐 👀 editorial in @CCR_AACR with @SilviaStacchia and @alegronchi aacrjournals.org/clincancerres/…

@jgong15 @NIH @theNCI @ConquerCancerFd @TowerCancer @CSCancerCenter @crisbergerot @PauloBergerot @CParkMD @montypal @NazliDizman @ASCO @NIHFunding @MOASC_Office @nataliagandur Congrats!!👏🏽 🥳

Incredibly fortunate/lucky to have my @NIH (5-yr) R01 converted to an @theNCI #R37 MERIT 7-yr award. Grateful to my mentors & the support of @ConquerCancerFd & @TowerCancer career development awards that paved the way for our work in novel #ctDNA assay development in #CRC (1/2)

Congrats @seacm! 👏🏽 👏🏽

Great way to cap off #colorectalcancer awareness month hosting our @CSCancerCenter #CRC research social w/Dr. Alessio Pigazzi @EdwinPosadasMD for a productive exchange of ideas, networking & future collabs w/PhDs & MDs in #CRC research @AGangiMD @fdossa @SGrivennikov @SekiEki

@drohan_ashley 🙏🏽

Congratulations Fahima!!!!

@HalletJulie @DeptSurgeryCS 🙏🏽

Congrats @fdossa! 🎉 And congrats to @DeptSurgeryCS - you’ve got an outstanding surgeon and scientist there! Can’t wait to work together 😀

@DeptSurgeryCS @CFerroneMD @AGangiMD @CSCancerCenter Looking forward to joining the fantastic teams at @DeptSurgeryCS and @CSCancerCenter !

Building on terrific #SSO2026 and @TARPSWG meetings, check out our📄on current dx & tx strategies for soft tissue sarcoma @BjsOpen, including recent technical advances and multiD approaches @ctosociety @SocSurgOnc @ESSOnews @_CSSO @FioreDoc @alegronchi academic.oup.com/bjsopen/articl…

ctDNA🩸: game-changer or expensive crystal ball?🔮 💡What surgeons should do with ctDNA in CRC, gastric & cholangiocarcinoma at #SSO2026 with @ColinCourtMD @fdossa @FlavioRochaMD & wrap-up by @rachnatshroff Join us in Phoenix👉🏻 tinyurl.com/55upkjsr

Sarcoma family dinner 💛thank you @SilviaStacchia and @alegronchi for welcoming us into your home, workplace and international sarcoma family! @TARPSWG @ctosociety @UofTSurgOnc

Thanks so much for the invite! Really enjoyed the discussion that followed about the future of #clinicaltrials in oncology - improving design and interpretation!